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LARSON RECEIVES RESEARCH
GRANT FOR CANCER STUDY
MISSOULA-Dr. Carl L. Larson, director of the Stel Ia Duncan Memorial Research Institute at
the University of Montana, has received a $13,480 grant from the National Cancer Institute
to study the antigens of BCG responsible for immunizing and treating a form of lung cancer.
"Baci I Ius Calmette-Guerin (BCG), is a vaccine commonty used to protect agalnst
tuberculosis and leprosy.

However, this tubercle bacteria is capable of ellclting broad

non-specific resistance, meaning that it is helpful in building resistance against many
diseases, including the lung cancer we are studying," satd Dr, Laison.
"Mice injected with BCG two weeks before the lnjectton of tumor eel Is developed only
62 lung tumors each compared with 126 tumors developed by mice not immunized with BCG.
Even more dramatic, mice given the injection of BCG mixed with tumor eel Is developed only
II tumors," added Dr. Larson.
"However, repeated injection of viable (alive) BCG may cause severe skin reactions.
We, therefore, need a better means of tapping BCG's immunogenic capabi I ities.
"If we can fractionate (break down) and isolate the antigen responsible for the
immunogenic effect of BCG, it then would be possible to develop a BCG booster program,"
said Larson.
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